Supernus Pharma (SUPN) Tops Q4 EPS by 3c

Supernus Pharma (NASDAQ: SUPN) reported Q4 EPS of ($0.10), $0.03 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $30.8 million versus the consensus estimate of $24.4 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• Franklin BSP Realty Trust (FBRT) Reiterated at Market Outperform by Citizens
• AutoZone beats profit view but misses on revenue